144 results on '"Porfiri, E."'
Search Results
2. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
3. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center
4. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer
5. Urinary Steroid Profiling as a High-Throughput Screening Tool for the Detection of Malignancy in Patients with Adrenal Tumors.
6. Effectiveness of the CRCAPRO program in identifying patients suspected for HNPCC
7. ‘Secrets and lies’ – the difficulties of communicating within families with inherited cancer syndromes
8. Loss of hMLH1 expression correlates with improved survival in stage III–IV ovarian cancer patients
9. Metastatic clear cell renal cell carcinoma patients with ECOG performance status 2 treated with pazopanib: The Pazo2 trial of efficacy and safety
10. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study
11. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
12. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both
13. 883P - Metastatic clear cell renal cell carcinoma patients with ECOG performance status 2 treated with pazopanib: The Pazo2 trial of efficacy and safety
14. 2600 Axitinib in second and further line for metastatic renal cell carcinoma (RCC): Real world data from 2 teaching hospitals in Birmingham, UK
15. 2633 Pattern of recurrence and outcomes for patients with Stage I Seminoma treated with adjuvant carboplatin: impact on follow-up schedule
16. 2604 Liver toxicity associated with the use of Pazopanib in renal cancer patients: UK teaching hospital experience
17. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
18. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
19. Analysis of survival after disease progression in patients with renal cell carcinoma (RCC) who failed treatment with sunitinib.
20. A retrospective analysis of patients with renal cancer receiving temsirolimus within a named patient program.
21. Identification of a molecular profile that may predict early relapse in patients undergoing multimodality therapy in muscle-invasive bladder cancer (MIBC).
22. Effect of the UK Postcode Lottery on Survival of Patients with Metastatic Renal Cancer: an Audit of Outcomes in Patients with Metastatic Renal Cancer Suitable for Treatment with Tyrosine Kinase Inhibitors
23. 49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)
24. Prolonged Response to Temsirolimus in a Pre-treated Patient with Metastatic Renal Cell Carcinoma and Poor Performance Status
25. The role of neoadjuvant chemotherapy in muscle invasive bladder cancer and correlation of clinical outcome with translational studies
26. Changes in the serum proteome associated with docetaxel chemotherapy
27. MSH2 splice site mutation and endometrial cancer
28. Interaction analysis of hMLH1 missense variants in patients selected for HNPCC syndrome
29. Elderly Patients with Advanced Non-Small Cell Lung Cancer
30. Prenylation of Ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange.
31. Determination of structural requirements for the interaction of Rab6 with RabGDI and Rab geranylgeranyltransferase.
32. DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18
33. ORIGINAL RESEARCH. Delays incurred during acute myocardial infarction: a comparative study of rural and urban populations in Greece.
34. Retinoic acid-induced granulocytic differentiation of HL60 human promyelocytic leukemia cells is preceded by downregulation of autonomous generation of inositol lipid-derived second messengers
35. Non-small cell lung cancer. Neuroresection of the solitary intracranial metastasis followed by radiochemotherapy.
36. Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1.
37. The farnesyl group activates Ras toward guanine nucleotide exchange catalyzed by the SOS protein
38. Beta-catenin gene analysis in oral squamous cell carcinoma
39. Urinary Steroid Profiling as a High-Throughput Screening Tool for the Detection of Malignancy in Patients with Adrenal Tumors
40. Mechanical characterization and geometric optimization of brick slabs for mechanical anchoring,Caratterizzazione meccanica e ottimizzazione geometrica di lastre in laterizio ad ancoraggio meccanico
41. Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5 -Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement
42. Stabilization of beta-catenin by genetic defects in melanoma cell lines
43. Evidence that inositol phospholipids, but not choline phospholipids, are a potential source of growth-regulating second messenger molecules in HL60 leukaemia cells
44. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
45. A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial.
46. Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?
47. Mitotane treatment in patients with metastatic testicular Leydig cell tumor associated with severe androgen excess.
48. Spontaneous CD4 + and CD8 + T-cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients.
49. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
50. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.